secwatch.observer — SEC 8-K summary
======================================

Issuer:     QuidelOrtho Corp (QDEL)
CIK:        0001906324
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001906324-26-000023
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

QuidelOrtho Q1 net loss $92M; revenue $620M; cuts full-year guidance
--------------------------------------------------------------------

- GAAP net loss $92M ($1.35 diluted loss per share); adjusted diluted EPS loss $0.04; revenue $620M.
- Point of Care revenue $113M (-34% YoY) on weak respiratory season; Labs $353M (-5%); Immunohematology $138M (+8%).
- Full-year 2026 guidance cut: revenue $2.70-2.75B (prev. $2.7-2.9B), adj. EBITDA $615-630M (prev. $630-670M), adj. EPS $1.80-2.00 (prev. $2.00-2.42).
- Acquired LEX Diagnostics in April for ultra-fast point-of-care molecular diagnostics platform.
- U.S. launch of High-Sensitivity Troponin and international rollout of VITROS 450 platform underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1906324/000190632426000023/0001906324-26-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1906324/000190632426000023/qdel-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001906324-26-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer